Klin Farmakol Farm. 2005;19(1):3-4

Adefovir dipivoxil - další naděje pro nemocné s chronickou hepatitidou B

doc. MUDr. Petr Husa CSc
Klinika infekčních chorob, FN Brno

Editorial k článku Stránský J. Léčba chronické hepatitidy B adefovir dipivoxilem

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Adefovir dipivoxil - další naděje pro nemocné s chronickou hepatitidou B. Klin Farmakol Farm. 2005;19(1):3-4.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The EASL Jury. EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002, Geneva, Switzerland. Consensus Statement (Short version). J Hepatol 2002; 38: 533-540. Go to original source... Go to PubMed...
    2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745. Go to original source... Go to PubMed...
    3. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38(Suppl): S90-S103. Go to original source... Go to PubMed...
    4. Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2000; 120: 1828-1853. Go to original source... Go to PubMed...
    5. Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD Practice Guideline. Hepatology 2001; 34: 1225-1241. Go to original source... Go to PubMed...
    6. Dienstag JL, Schiff ER, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63. Go to original source... Go to PubMed...
    7. Liaw F, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180. Go to original source... Go to PubMed...
    8. Tassopoulos NC, olpes R., Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896. Go to original source... Go to PubMed...
    9. Liaw F. Results of lamivudine in Asian trials. Proceedings of EASL International Consensus Conference on Hepatitis B, Geneva, 2002.
    10. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. Go to original source... Go to PubMed...
    11. Hadziyannis S., Tassopoulos N, Chang TT, et al. Three year study of adefovir dipivoxil (AD) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long-term safety and efficacy study (LTSES). J Hepatol 2004; 40: 17. Go to original source...
    12. Westland CE, ang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96-103. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.